1. A randomized clinical trial of omega-3 fatty acid and vitamin D supplementation on electrocardiographic risk profiles.
- Author
-
Tikkanen, Jani T., Soliman, Elsayed Z., Pester, Julie, Danik, Jacqueline S., Gomelskya, Natalia, Copeland, Trisha, Lee, I.-Min, Buring, Julie E., Manson, JoAnn E., Cook, Nancy R., and Albert, Christine M.
- Subjects
OMEGA-3 fatty acids ,DIETARY supplements ,CLINICAL trials ,VITAMIN D ,VENTRICULAR arrhythmia ,ARRHYTHMIA ,DOCOSAHEXAENOIC acid ,VAGAL tone - Abstract
Beneficial and adverse associations with arrhythmias have been reported for omega-3 fatty acids (omega-3 FA) and Vitamin D. The 12 lead electrocardiogram (ECG) contains quantitative measures reflecting diverse aspects of electrophysiology that might provide insights into mechanisms underlying these associations. In a pre-specified ancillary study of the VITaminD and omegA-3 (VITAL) trial, we examined the effect of 1 g of marine omega-3 FA per day, comprised of 460 mg eicosapentanoic acid and 380 mg of docosahexaenoic acid, and 2000 IU VitaminD
3 per day on ECG characteristics associated with atrial and ventricular arrhythmias among individuals age 50 years or greater. A total of 911 study participants underwent ECGs at baseline and again at 2 years after the randomization. Individuals randomized to active omega-3 FA demonstrated significant net increase in PR-interval duration (p = 0.005) and P-wave duration (p = 0.03) as well significant net decrease in P-wave amplitude (p = 0.037) as compared to placebo. RMSSD increased to a greater extent in the omega-3 FA arm compared to placebo (p = 0.040). For Vitamin D3 , the Cornell voltage increased to a lesser extent in the participants assigned to active treatment as compared to placebo (p = 0.044). There were no other significant differences in QRS, QTc, Cornell voltage or heart rate. Thus, randomized treatment with omega-3 FA supplements resulted in changes on the ECG that are potentially reflective of heightened vagal tone and/or slowing of intraatrial and AV conduction. Vitamin D3 supplementation resulted in modest reductions in progressive LV voltage suggestive of a potential antihypertrophic effect. Trial registration ClinicalTrials.gov Identifiers: NCT01169259, NCT02178410 (06/26/2010 and 06/30/2014). [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF